|
SG11201907870VA
(en)
|
2017-02-28 |
2019-09-27 |
Vor Biopharma Inc |
Compositions and methods for inhibition of lineage specific proteins
|
|
CA3110837A1
(en)
|
2018-08-28 |
2020-03-05 |
Vor Biopharma Inc. |
Genetically engineered hematopoietic stem cells and uses thereof
|
|
EP3850088A4
(en)
|
2018-09-07 |
2023-07-19 |
Beam Therapeutics, Inc. |
Compositions and methods for improving base editing
|
|
EP3918077A4
(en)
*
|
2019-01-31 |
2023-03-29 |
Beam Therapeutics, Inc. |
NUCLEOBASE EDITORS WITH REDUCED OFF-TARGET DEAMINATION AND METHODS OF USING THEM TO MODIFY A NUCLEOBASE TARGET SEQUENCE
|
|
WO2020168122A1
(en)
|
2019-02-13 |
2020-08-20 |
Beam Therapeutics Inc. |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
AU2020232691B2
(en)
|
2019-03-05 |
2023-06-29 |
Nkarta, Inc. |
CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
|
|
JP7831937B2
(ja)
*
|
2019-09-03 |
2026-03-17 |
クリエイト・メディシンズ，インコーポレーテッド |
ゲノム組込みのための方法および組成物
|
|
EP4034138A4
(en)
|
2019-09-27 |
2024-07-31 |
Beam Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
|
|
US20240238344A1
(en)
*
|
2020-08-28 |
2024-07-18 |
Vor Biopharma Inc. |
Compositions and methods for cd123 modification
|
|
WO2022056459A1
(en)
*
|
2020-09-14 |
2022-03-17 |
Vor Biopharma, Inc. |
Compositions and methods for cd5 modification
|
|
WO2022061115A1
(en)
*
|
2020-09-18 |
2022-03-24 |
Vor Biopharma Inc. |
Compositions and methods for cd7 modification
|
|
CN116322716A
(zh)
*
|
2020-09-23 |
2023-06-23 |
克里斯珀医疗股份公司 |
Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性
|
|
AU2021347359A1
(en)
*
|
2020-09-25 |
2023-05-18 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
US20230364146A1
(en)
*
|
2020-09-30 |
2023-11-16 |
Vor Biopharma Inc. |
Compositions and methods for cd30 gene modification
|
|
US20250195650A1
(en)
*
|
2020-11-04 |
2025-06-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for enhancing efficacy of therapeutic immune cells
|
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
JP2023552998A
(ja)
*
|
2020-12-03 |
2023-12-20 |
ンカルタ・インコーポレイテッド |
効力および持続性の増強のために免疫細胞を操作する方法、ならびに免疫療法における操作された細胞の使用
|
|
CR20230305A
(es)
*
|
2020-12-11 |
2023-11-10 |
Intellia Therapeutics Inc |
Polinucleótidos, composiciones y métodos para la edición del genoma que implican desaminación
|
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
|
CA3204417A1
(en)
*
|
2021-01-29 |
2022-08-04 |
Allogene Therapeutics, Inc. |
Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
|
|
WO2022215978A1
(ko)
*
|
2021-04-05 |
2022-10-13 |
주식회사 셀렌진 |
Pdcd-1 유전자에 상보적인 가이드 rna 및 이의 용도
|
|
CN113179160B
(zh)
*
|
2021-04-15 |
2022-03-18 |
中国电子科技集团公司第三十研究所 |
一种适用于qkd中私钥放大的最优输入码长处理方法及单元
|
|
CA3217458A1
(en)
*
|
2021-05-06 |
2022-11-10 |
Spyro Mousses |
Sirna constructs for inhibiting gene expression in targeted cancer cells
|
|
AU2022272235A1
(en)
*
|
2021-05-11 |
2023-12-21 |
Create Medicines, Inc. |
Methods and compositions for genomic integration
|
|
CA3228879A1
(en)
*
|
2021-08-16 |
2023-02-23 |
Beam Therapeutics Inc. |
Persistent allogeneic modified immune cells and methods of use thereof
|
|
CA3225082A1
(en)
|
2021-08-27 |
2023-03-02 |
Brian C. Thomas |
Enzymes with ruvc domains
|
|
WO2023034742A1
(en)
*
|
2021-08-30 |
2023-03-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
T cells with cell-surface expression of adenosine deaminase and uses thereof
|
|
AU2022366987A1
(en)
|
2021-10-14 |
2024-05-16 |
Arsenal Biosciences, Inc. |
Immune cells having co-expressed shrnas and logic gate systems
|
|
CN113980896B
(zh)
*
|
2021-10-27 |
2023-10-20 |
中国人民解放军军事科学院军事医学研究院 |
Irf1在调控间充质干细胞免疫调节作用及产品上的应用
|
|
EP4426338A2
(en)
*
|
2021-11-03 |
2024-09-11 |
Intellia Therapeutics, Inc. |
Cd38 compositions and methods for immunotherapy
|
|
WO2023086931A2
(en)
*
|
2021-11-12 |
2023-05-19 |
Georgia Tech Research Corporation |
Adenosine deaminase 1 compositions and methods for using same
|
|
MX2024006257A
(es)
|
2021-11-24 |
2024-07-29 |
Metagenomi Inc |
Sistemas de endonucleasas.
|
|
CA3240846A1
(en)
*
|
2021-12-14 |
2023-06-22 |
The Trustees Of The University Of Pennsylvania |
Cd5 modified cells comprising chimeric antigen receptors (cars) for treatment of solid tumors
|
|
CN114774364B
(zh)
*
|
2022-04-26 |
2024-04-26 |
深圳市体内生物医药科技有限公司 |
一种嵌合抗原受体t细胞及其制备方法和应用
|
|
EP4532697A2
(en)
*
|
2022-06-03 |
2025-04-09 |
Beam Therapeutics Inc. |
Modified regulatory t cells and methods of using the same
|
|
IL317811A
(en)
|
2022-07-25 |
2025-02-01 |
Interius Biotherapeutics Inc |
Mutated polypeptides, compositions containing them and uses thereof
|
|
WO2024054062A1
(ko)
*
|
2022-09-08 |
2024-03-14 |
주식회사 에이조스바이오 |
세포 내 형질주입을 위한 신규한 폴리펩타이드 조성물
|
|
EP4587570A2
(en)
*
|
2022-09-16 |
2025-07-23 |
Arsenal Biosciences, Inc. |
Immune cells with combination gene perturbations
|
|
CN120239746A
(zh)
*
|
2022-09-19 |
2025-07-01 |
图恩疗法股份有限公司 |
用于调节t细胞功能的组合物、系统和方法
|
|
JP2025532979A
(ja)
*
|
2022-09-30 |
2025-10-03 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
養子ｔ細胞治療薬を増強させるための組成物および方法
|
|
KR20250158048A
(ko)
|
2023-03-03 |
2025-11-05 |
아스널 바이오사이언시스, 인크. |
Psma 및 ca9을 표적으로 하는 시스템
|
|
WO2024186841A2
(en)
*
|
2023-03-06 |
2024-09-12 |
La Jolla Institute For Immunology |
Nfkbid cells and methods for immunotherapy
|
|
WO2024193562A1
(zh)
*
|
2023-03-21 |
2024-09-26 |
苏州沙砾生物科技有限公司 |
一种修饰的细胞及其用途
|
|
WO2024215414A1
(en)
*
|
2023-04-12 |
2024-10-17 |
Beam Therapeutics Inc. |
Modified immune effector cells with improved efficacy
|
|
EP4455157A1
(en)
*
|
2023-04-27 |
2024-10-30 |
Fundacion Publica Andaluza Progreso Y Salud M.P.- Fps |
Polynuceotide for t cell specific transgene expression
|
|
IL324508A
(en)
*
|
2023-05-16 |
2026-01-01 |
Prime Medicine Inc |
Genome editing compositions targeting the b2m gene and methods of use
|
|
CN121195068A
(zh)
*
|
2023-05-26 |
2025-12-23 |
爱迪塔斯医药公司 |
靶向cd70表达的crispr相关方法和组合物
|
|
CN116590237B
(zh)
*
|
2023-05-29 |
2023-10-31 |
上海贝斯昂科生物科技有限公司 |
一种遗传修饰的自然杀伤细胞及其制备和用途
|
|
WO2025111533A1
(en)
*
|
2023-11-22 |
2025-05-30 |
The General Hospital Corporation |
Car-t cells comprising a cdkn1b gene knockout and methods of use thereof
|
|
WO2025119307A1
(zh)
*
|
2023-12-06 |
2025-06-12 |
北京齐禾生科生物科技有限公司 |
优化的qbe碱基编辑系统及其应用
|
|
WO2025122896A1
(en)
*
|
2023-12-08 |
2025-06-12 |
The Trustees Of The University Of Pennsylvania |
Cd5 modified cells comprising heterologous tcrs and methods of using the same
|
|
WO2025238594A2
(en)
*
|
2024-05-16 |
2025-11-20 |
Fondazione Istituto Italiano Di Tecnologia |
DESIGN OF SYNTHETIC miRNAS TO RESTORE THE CORRECT GENE DOSAGE OF GENES ASSOCIATED WITH T LYMPHOCYTE EXHAUSTION
|